Heartflow (NASDAQ:HTFL) CFO Sells 6,640 Shares

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 6,640 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $50.03, for a total value of $332,199.20. Following the completion of the transaction, the chief financial officer owned 214,503 shares in the company, valued at approximately $10,731,585.09. The trade was a 3.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The shares were sold at an average price of $49.69, for a total value of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The stock was sold at an average price of $50.60, for a total value of $297,325.60.

Heartflow Trading Down 2.5%

NASDAQ HTFL traded down $1.18 during mid-day trading on Thursday, hitting $45.49. The company’s stock had a trading volume of 2,256,650 shares, compared to its average volume of 1,550,843. The firm has a market capitalization of $3.96 billion and a price-to-earnings ratio of -24.86. The company’s 50 day simple moving average is $34.73 and its 200 day simple moving average is $30.50. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $51.78.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. The firm had revenue of $64.08 million for the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. As a group, research analysts forecast that Heartflow, Inc. will post -0.75 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HTFL shares. JPMorgan Chase & Co. lifted their price target on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Piper Sandler restated an “overweight” rating and issued a $45.00 target price (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. Stifel Nicolaus upped their price target on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Finally, Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.88.

Institutional Trading of Heartflow

Several hedge funds have recently added to or reduced their stakes in the stock. XXEC Inc. bought a new position in shares of Heartflow during the 2nd quarter valued at approximately $2,524,764,000. BlackRock Inc. purchased a new position in Heartflow in the second quarter valued at approximately $152,502,000. Wellington Management Group LLP bought a new position in Heartflow during the third quarter valued at $164,263,000. Bamco Inc. NY bought a new stake in shares of Heartflow in the second quarter valued at $94,625,000. Finally, Jupiter Topco LLC purchased a new position in shares of Heartflow during the 2nd quarter valued at $70,983,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.